Rituximab biosimilar (Prestige BioPharma)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameRituximab biosimilar (Prestige BioPharma)
Drug Alias NamePBP-1506
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionB-lymphocyte antigen CD20 inhibitors
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsArthritisLymphoma, Non-Hodgkin
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySingapore
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesPrestige BioPharma Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPrestige BioPharma Ltd
Active IndicationsN/A
Inactive IndicationsArthritisLymphoma, Non-Hodgkin

Other Information

ATC CodeN/A
Related LinksN/A